In patients with a transient ischaemic attack (TIA) or a minor acute ischaemic stroke with ipsilateral stenosis of the cervicocranial vasculature, the P2Y12 inhibitor ticagrelor added to aspirin reduced the risk of recurrent stroke within 30 days by 27% in the THALES trial .
Among patients with a TIA or minor ischaemic strokes, ipsilateral atherosclerotic stenosis of cervicocranial vasculature entails the highest risk of recurrent vascular events, explained first author Prof. Pierre Amarenco (Paris University, France) . Ticagrelor monotherapy was not superior to aspirin in the SOCRATES trial . However, in the subgroup of patients with ipsilateral atherosclerotic stenosis, ticagrelor was superior to aspirin .
The THALES trial (NCT03354429) randomised 11,016 patients to ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice dai...
Please login to read the full text of the article.
If you have no account yet, please register now.
« AF monitoring following cardiovascular surgery Next Article
Longer chest compression pause worsens outcomes after paediatric IHCA »